Ogivri 440 mg/20 ml (IV Infusion)
440 mg vial: ৳ 60,190.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Trastuzumab |
| Company | Mylan laboratories ltd |
Indications
- Adjuvant treatment of HER2 overexpressing node-positive/negative ER/PR negative breast cancer
- Metastatic breast cancer treatment
- Metastatic gastric cancer treatment
Pharmacology
Inhibits the proliferation of human tumor cells that overexpress HER2, mediates antibody-dependent cellular cytotoxicity (ADCC)
Dosage
- Administered as intravenous infusion
- Different doses and schedules for adjuvant and metastatic treatment of breast cancer
- Multiple-dose use solution for metastatic gastric cancer treatment
Administration
- Reconstitution with diluent and storage conditions
- Visual inspection for particulate matter and discoloration before administration
- Refrigeration and shelf life of the reconstituted product
Interaction
Increased risk of cardiac dysfunction with anthracycline use after stopping Ogivri
Side Effects
- Serious adverse reactions such as cardiomyopathy and infusion reactions
- Common adverse reactions include fever, nausea, vomiting, and neutropenia
Pregnancy & Lactation
- Can cause fetal harm if administered to pregnant women
- Necessity of effective contraception during treatment and for 7 months following the last dose of Trastuzumab
Precautions & Warnings
- Potential for cardiomyopathy and left ventricular cardiac dysfunction
- Necessity of thorough cardiac monitoring
- Infusion reactions and embryo-fetal toxicity
- Risk of pulmonary toxicity and exacerbated chemotherapy-induced neutropenia
Use in Special Populations
Safety and effectiveness not established in pediatric patients
Reconstitution
Reconstitution with Bacteriostatic Water for Injection or Sterile Water for Injection based on patient hypersensitivity to preservative
Storage Conditions
- Refrigeration and protection from light for the vial
- Shelf life and usage recommendations for reconstituted Ogivri solution